Abstract
9510 Background: Gene expression arrays reveal several breast cancer (BrCa) subtypes, with the basal-like subtype (BBT) carrying a poor prognosis (Sorlie T, PNAS 2003). Multiple BrCa microarray datasets (Sorlie et al PNAS 2003; van't Veer et al, Nature 2002; Sotiriou et al, PNAS 2003) suggest that 90% of BBT are ER-negative, PR-negative, and HER-2 nonamplified (Perou C, unpublished). Thus, this “triple negative” phenotype may be used to identify and determine the frequency of BBT. Methods: Data were obtained from the CBCS, a population-based case-control study of BrCa causation among African-American (AA) and non-African American (nonAA) women. The CBCS oversampled AA and women under the age of 50. HER-2 was determined by UNC Lineberger Immunohistochemistry (IHC) Core. We determined the proportion of triple negative BrCa by race (AA vs. non-AA) and by stage, mitotic index (>10 vs. ≤10) nuclear grade and histologic grade (grade 3 vs. 1–2). Results: 657 incident BrCa were evaluated from Phase I of the CBCS, including 260 AA and 397 nonAA women. 26.2% of all BrCa were triple negative, however this phenotype was significantly more frequent in AA (33.9% vs. 21.2%, p=0.0003), premenopausal women (30.3% vs. 21.9%, p=0.02), mitotic index > 10 (45.8% vs. 11.3%, p<0.0001), and nuclear or histologic grade 3 tumors (p=0.0001). The highest prevalence of triple negative BrCa occurred among premenopausal AA women (44.3%) compared with postmenopausal AA women (24.6%) (p=0.0008). In multivariate models combining all factors, the significant predictors of the triple negative phenotype were high mitotic index (p<0.0001), high nuclear or histologic grade (p<0.0001 both), and race (p=0.03). Conclusions: The poor-prognosis BBT subtype is strongly associated with high proliferative capacity (mitotic index > 10) and nuclear pleomorphism. In a large population-based study, the triple negative phenotype characteristic of BBT is markedly more common in AA women, particularly premenopausal AA women. The high proportion of BBT likely plays a role in the poor prognosis experienced by AA women with BrCa. (supported by NCI (SPORE CA58223), NIH (GCRC MO1RR00046). No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.